BriaCell Therapeutics gets license for anti-cancer agent sCD80 from UMBC
BriaCell Therapeutics has signed an exclusive licensing deal with the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for cancer treatment. sCD80 was developed originally by Suzanne Ostrand-Rosenberg from the Emeritus Faculty at UMBC. According to BriaCell Therapeutics, sCD80 was well-tolerated in animal models, and by […]